Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

Abstract: Compositions and methods for providing anesthesia to the eye, for treating or preventing inflammatory disorders in the eye, or for treating or preventing ocular infections, are disclosed. The compositions include a glycosaminoglycan, such as hyaluronic acid, in a concentration suitable for achieving a desired viscosity, as well as an active agent, such as an anesthetic, anti-inflammatory, antimicrobial, antiproliferative, antimetabolite, prostaglandin, antioxidant, TGF-beta, or mitomycin C.

Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

Abstract: Hydrocinnamate compounds that exhibit proteasome modulation activity, and in particular, proteasome inhibitory activity, can be used to topically or systemically treat ocular disorders associated with proteasome activity. The hydrocinnamate compounds can be applied to the eye, in any of a variety of ocular formulations, to treat ocular disorders, such as ocular rosacea, diabetic retinopathy, macular degeneration, and dry eye. The hydrocinnamate compounds can also be administered systemically to treat ocular disorders.

Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

Abstract: Compositions and methods for providing anesthesia to the eye, for treating or preventing inflammatory disorders in the eye, or for treating or preventing ocular infections, are disclosed. The compositions include a glycosaminoglycan, such as hyaluronic acid, in a concentration suitable for achieving a desired viscosity, as well as an active agent, such as an anesthetic, anti-inflammatory, antimicrobial, antiproliferative, antimetabolite, prostaglandin, antioxidant, TGF-beta, or mitomycin C.